Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis
International Journal of Rheumatic Diseases · 2023
DOI: 10.1111/1756-185x.14558 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2023. Verfasst von Ping-Han Tsai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Gout, Myocardial Infarction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objectives
To evaluate the influence of febuxostat on adverse events and mortality in gout.
Methods
We retrospectively enrolled patients with newly diagnosed gout and prescribed urate‐lowering therapy between 2006 and 2017 from the Taiwan National Health Insurance Database. These patients were divided into 2 groups: with and without comorbidities ( n = 294 847 and 194 539). An interrupted time series analysis with adjustments for demographics, comorbidities, and comedication by propensity score‐based stabilized weights was used to compare the trend of adverse events and mortality before vs after febuxostat was introduced in 2012.
Results
The proportion of febuxostat use gradually increased from 0% in 2012 to 30% in those with comorbidities and 10% in those without comorbidities in 2017. Allopurinol use decreased from 30% in 2012 to 10% in 2017. The slope of the 1‐year incidence rate of Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (per 10 000 patients) significantly reduced after 2012 in those with and without comorbidities (−0.375 per quarter, P = .015 and −.253 per quarter, P = .049). The slope of the 3‐year incidence rate of acute myocardial infarction (AMI) (per 1000 patients), percutaneous coronary intervention (PCI) (per 1000 patients), and all‐cause mortality (per 100 patients) significantly increased after 2012 in those with comorbidities (+0.207 per quarter, P = .013; +.389 per quarter, P = .002; +.103 per quarter, P = .001).
Conclusions
Febuxostat may reduce SJS and TEN in all gout patients but increase AMI, PCI, and all‐cause mortality in gout patients with comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
- Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.
- Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
- Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
- Department of Public Health, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
- Biostatistics Core Laboratory, Molecular Medicine Research Center, Chang Gung University, Taoyuan City, Taiwan.
ORCID-Profile: Ping-Han Tsai, Chang-Fu Kuo, Jia-Rou Liu, Pei-Ru Li, Lai-Chu See
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Tsai, P. H., Kuo, C. F., Liu, J. R., Li, P. R., & See, L. C. (2023). Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14558
Vancouver
Tsai PH, Kuo CF, Liu JR, Li PR, See LC. Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis. International Journal of Rheumatic Diseases. 2023. doi:10.1111/1756-185x.14558
BibTeX
@article{Tsai2023,
author = {Tsai, Ping-Han and Kuo, Chang-Fu and Liu, Jia-Rou and Li, Pei-Ru and See, Lai-Chu},
title = {Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis},
journal = {International Journal of Rheumatic Diseases},
year = {2023},
doi = {10.1111/1756-185x.14558}
}
EUVIMED